Intensity Therapeutics, Inc. Common stock (INTS NASDAQ) stock market data APIs
$3.3848
0(0%)
as of October 30, 2026
Try our APIs with
free plan!
Intensity Therapeutics, Inc. Common stock Financial Data Overview
Price chart is built with
Anychart
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Prev. Close
3.3848
Open
3.3887
High
3.4287
Low
3.1984
52 wk Range
3-17.675
Market Cap
11 101 K
Shares Outstanding
3 265 K
Beta
3.079
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Intensity Therapeutics, Inc. Common stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Intensity Therapeutics, Inc. Common stock data using free add-ons & libraries
Get Intensity Therapeutics, Inc. Common stock Fundamental Data
Intensity Therapeutics, Inc. Common stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Intensity Therapeutics, Inc. Common stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.94
Get Intensity Therapeutics, Inc. Common stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intensity Therapeutics, Inc. Common stock News
New
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohort No invas...
Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3
Earnings Call Insights: Intensity Therapeutics (INTS) Q2 2026 MANAGEMENT VIEW * "It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studi...
Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress
(RTTNews) - Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, announced the appointment of James Ahlers as Chief Financial Office...
Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity Therapeutics
Apple (AAPL) Shares in Apple (AAPL) were higher in pre-market trading following the tech giant's fiscal fourth-quarter results, which exceeded Wall Street's expectations. Apple posted total revenue ...
Get Intensity Therapeutics, Inc. Common stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.